antibiotics NNS N
. . N

The DT N
geometric JJ N
means NNS N
of IN N
AUCi.v NNP N
. . N

Links NNS N
between IN N
multisensory NN N
processing NN N
and CC N
autism NN N
. . N

The DT N
effect NN N
of IN N
choline NN N
on IN N
egg NN N
quality NN N
was VBD N
minimal JJ N
when WRB N
hens NNS N
were VBD N
fed VBN N
a DT N
corn-soybean JJ N
meal-based JJ N
diet NN N
from IN N
19 CD N
to TO N
68 CD N
wk NN N
of IN N
age NN N
. . N

Relative JJ N
risk NN N
reduction NN N
24 CD N
% NN N
( ( N
p JJ N
< NNP N
0.031 CD N
) ) N
. . N

RESULTS NNP N
Significant JJ N
differences NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
initial JJ N
values NNS N
were VBD N
found VBN N
after IN N
a DT N
2 CD N
mm NN N
marginal JJ N
bone NN N
removal NN N
( ( N
Osstell/Periotest NNP N
) ) N
; : N
for IN N
a DT N
peri-apical JJ N
bone NN N
lesion NN N
, , N
after IN N
removal NN N
of IN N
5 CD N
mm NN N
( ( N
Osstell NNP N
) ) N
or CC N
8 CD N
mm NN N
( ( N
Periotest NNP N
) ) N
; : N
for IN N
a DT N
6-mm-long JJ N
dehiscence NN N
, , N
after IN N
removal NN N
up RB N
to TO N
180 CD N
degrees NNS N
of IN N
the DT N
implant JJ N
perimeter NN N
( ( N
Osstell/Periotest NNP N
) ) N
; : N
for IN N
a DT N
3-mm-wide JJ N
dehiscence NN N
, , N
after IN N
removal NN N
of IN N
10 CD N
mm NN N
( ( N
Osstell NNP N
) ) N
or CC N
6 CD N
mm NN N
( ( N
Periotest NNP N
) ) N
. . N

Blood NN N
samples NNS N
were VBD N
collected VBN N
at IN N
6 CD N
, , N
7 CD N
, , N
and CC N
12 CD N
months NNS N
. . N

and CC N
salbutamol JJ N
200 CD N
microg NN N
p.r.n NN N
. . N

Middle NNP N
cerebral JJ N
arterial JJ N
blood NN N
flow NN N
velocity NN N
and CC N
hemodynamics NNS N
in IN N
heart NN N
surgery NN N
. . N

Of IN N
the DT N
patients NNS p
who WP N
received VBD N
C/A NNP N
, , N
58 CD N
% NN N
responded VBD N
to TO N
the DT N
initial JJ N
dosage NN N
of IN N
150/2500 CD N
mg/d NN N
, , N
and CC N
8 CD N
% NN N
of IN N
the DT N
patients NNS p
responded VBD N
to TO N
the DT N
double JJ N
dosage NN N
; : N
34 CD N
% NN N
did VBD N
not RB N
experience VB N
pain NN N
relief NN N
. . N

Intake NNP N
and CC N
liking NN N
of IN N
carrots NNS N
were VBD N
greater JJR N
than IN N
green JJ N
beans NNS N
. . N

The DT N
SMILE NNP N
( ( N
self-management JJ N
education NN N
for IN N
adults NNS N
with IN N
poorly RB N
controlled VBN N
epilepsy NN N
) ) N
trial NN N
evaluates VBZ N
a DT N
complex JJ N
service NN N
intervention NN N
that WDT N
involves VBZ N
a DT N
2-day JJ N
self-management JJ N
course NN N
with IN N
the DT N
aim NN N
of IN N
improving VBG N
quality NN N
of IN N
life NN N
and CC N
clinical JJ N
outcomes NNS N
. . N

Endoscopies NNS N
were VBD N
performed VBN N
1 CD N
week NN N
before IN N
and CC N
after IN N
treatment NN N
. . N

The DT N
1 CD N
to TO N
3-year JJ N
OS NNP N
were VBD N
77.9 CD N
% NN N
, , N
44.4 CD N
% NN N
, , N
37.3 CD N
% NN N
and CC N
75.8 CD N
% NN N
, , N
56.3 CD N
% NN N
, , N
41.7 CD N
% NN N
respectively RB N
( ( N
P NNP N
= NNP N
0.79 CD N
) ) N
. . N

One-year JJ N
patient NN N
survival NN N
was VBD N
85.7 CD N
% NN N
( ( N
placebo NN N
) ) N
and CC N
88.8 CD N
% NN N
( ( N
steroid NN N
) ) N
( ( N
p JJ N
= NNP N
0.572 CD N
) ) N
. . N

Patients NNS N
receiving VBG N
the DT N
high-dose JJ N
pralidoxime JJ N
regimen NNS N
required VBD N
less JJR N
atropine JJ N
during IN N
the DT N
first JJ N
24 CD N
h NN N
than IN N
controls NNS N
( ( N
median JJ N
6 CD N
mg NN N
vs NN N
30 CD N
mg NN N
; : N
difference NN N
24 CD N
mg NN N
[ VBD N
95 CD N
% NN N
CI NNP N
24-26 CD N
, , N
p VBZ N
< JJ N
0.0001 CD N
] NN N
) ) N
. . N

Commonest NNP N
adverse JJ N
events NNS N
were VBD N
the DT N
development NN N
of IN N
hypertension NN N
or CC N
tachycardia NN N
and CC N
intolerable JJ N
flushing NN N
or CC N
nausea NN N
. . N

Thirty CD N
percent NN N
( ( N
n JJ N
= NNP N
3 CD N
) ) N
of IN N
patients NNS p
taking VBG N
ZNS NNP N
discontinued VBD N
the DT N
study NN N
due JJ N
to TO N
side VB N
effects NNS N
( ( N
fatigue NN N
, , N
headache NN N
, , N
paresthesias NN N
) ) N
while IN N
taking VBG N
100 CD N
mg JJ N
per IN N
day NN N
. . N

All DT N
tooth JJ N
specimens NNS N
were VBD N
sputter-coated JJ N
with IN N
gold NN N
for IN N
4 CD N
min NNS N
and CC N
examined VBD N
using VBG N
a DT N
scanning VBG N
electron NN N
microscope NN N
. . N

Femoral NNP N
neck NN N
osteotomy NN N
guide NN N
for IN N
total JJ N
hip NN N
arthroplasty NN N
. . N

At IN N
that DT N
intake NN N
, , N
whites NNS N
accumulated VBD N
385 CD N
+/- JJ N
153 CD N
mmol NNS N
compared VBN N
with IN N
909 CD N
+/- JJ N
153 CD N
mmol NN N
for IN N
blacks NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
combination NN N
phase NN N
, , N
RPF NNP N
increased VBN o
by IN N
123 CD N
+/- JJ N
36 CD N
mL/min NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Follow-up NN N
was VBD N
at IN N
15 CD N
and CC N
33 CD N
weeks NNS N
post-randomisation NN N
when WRB N
assessments NNS N
of IN N
mental JJ N
health NN N
were VBD N
made VBN N
using VBG N
measures NNS N
which WDT N
included VBD N
the DT N
CIS-R NNP N
. . N

CLINICAL NNP N
TRIAL NNP N
NCT00681447 NNP N
. . N

The DT N
Symptom NNP N
Distress NNP N
Scale NNP N
( ( N
SDS NNP N
) ) N
, , N
Revised VBN N
Piper NNP N
Fatigue NNP N
Scale NNP N
( ( N
PFS NNP N
) ) N
, , N
and CC N
the DT N
State NNP N
Anxiety NNP N
Inventory NNP N
( ( N
SAI NNP N
) ) N
were VBD N
used VBN N
to TO N
measure VB N
symptom JJ N
distress NN N
. . N

SETTING NNP N
National NNP N
Survey NNP N
for IN N
Children NNP N
's POS N
Health NNP N
2003-2004 CD N
telephone NN N
interview NN N
. . N

Age NNP N
was VBD N
not RB N
associated VBN N
with IN N
OS NNP N
( ( N
P NNP N
= NNP N
0.13 CD N
) ) N
. . N

Low JJ N
residual JJ N
platelet NN N
reactivity NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
and CC N
female JJ N
gender NN N
( ( N
p JJ N
= NNP N
0.29 CD N
) ) N
were VBD N
independent JJ N
predictors NNS N
of IN N
bleeding VBG N
events NNS N
. . N

Adverse JJ N
events NNS N
were VBD N
mainly RB N
mild JJ N
. . N

All DT N
patients NNS p
survived VBD N
PBSCT NNP N
. . N

) ) N
and CC N
100 CD N
mg NN N
twice RB N
daily RB N
( ( N
b.i.d NN N
. . N

Seventy-eight JJ N
patients NNS p
were VBD N
randomized VBN N
( ( N
Evr NNP N
n RB N
= VBZ N
52 CD N
; : N
CsA NNP N
n VBD N
= NNP N
26 CD N
) ) N
. . N

) ) N
and CC N
vindesine NN N
( ( N
3 CD N
mg/m NN N
( ( N
2 CD N
) ) N
i.v NN N
. . N

14 CD N
& CC N
16 CD N
) ) N
. . N

Patients NNS N
received VBD N
3 CD N
to TO N
9 CD N
breaths NNS N
( ( N
6 CD N
? g/breath N
) ) N
of IN N
inhaled VBN N
treprostinil NN N
4 CD N
times/day NN N
. . N

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Single-dose JJ N
anastrozole NN N
at IN N
5 CD N
mg NN N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
, , N
10 CD N
mg NN N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
, , N
20 CD N
mg NN N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
, , N
or CC N
30 CD N
mg NN N
( ( N
n JJ N
= NNP N
38 CD N
) ) N
or CC N
a DT N
5-day JJ N
course NN N
of IN N
CC NNP N
at IN N
50 CD N
mg/d NN N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
as IN N
starting VBG N
doses NNS N
. . N

OBJECTIVE NNP N
Evaluation NN N
of IN N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
6 CD N
% NN N
coriander NN N
oil NN N
in IN N
unguentum NN N
leniens NNS N
in IN N
the DT N
treatment NN N
of IN N
interdigital JJ N
tinea NN N
pedis NN N
. . N

Rehabilitation NNP N
outcomes VBZ N
following VBG N
percutaneous JJ N
coronary JJ N
interventions NNS N
( ( N
PCI NNP N
) ) N
. . N

In IN N
the DT N
concurrent NN N
arm NN N
, , N
35 CD N
of IN N
48 CD N
evaluable JJ N
patients NNS p
( ( N
73 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
58 CD N
% NN N
-85 NNP N
% NN N
) ) N
had VBD N
a DT N
complete JJ N
response NN N
. . N

Independent JJ N
evaluators NNS N
, , N
parents NNS N
, , N
and CC N
adolescents NNS N
rated VBN N
symptom JJ N
severity NN N
at IN N
baseline NN N
and CC N
posttreatment/postwaitlist NN N
. . N

Serious JJ N
adverse JJ N
events NNS N
during IN N
treatment NN N
due JJ N
to TO N
psychiatric JJ N
conditions NNS N
were VBD N
associated VBN N
with IN N
AR-R15896AR NNP N
( ( N
3 CD N
vs. FW N
0 CD N
) ) N
. . N

Double-blind JJ N
placebo-controlled JJ N
studies NNS N
. . N

Prior NNP N
focal JJ N
( ( N
n JJ N
= NNP N
31 CD N
) ) N
or CC N
panretinal JJ N
( ( N
n JJ N
= NNP N
25 CD N
) ) N
laser JJR N
coagulation NN N
was VBD N
permitted VBN N
. . N

intravenously RB N
or CC N
0.5 CD N
g NNS N
imipenem JJ N
q.i.d NN N
. . N

) ) N
at IN N
25 CD N
% NN N
and CC N
a DT N
full-fatted JJ N
diatom NN N
biomass NN N
( ( N
FD NNP N
; : N
Staurosira NNP N
spp NN N
. . N

Sociodemographic NNP N
data NNS N
and CC N
clinical JJ N
features NNS N
were VBD N
assessed VBN N
. . N

The DT N
age NN N
range NN N
was VBD N
13-50 JJ N
years NNS N
( ( N
mean JJ N
33.6 CD N
years NNS N
) ) N
. . N

There EX N
were VBD N
also RB N
no DT N
significant JJ N
inter-group JJ N
differences NNS N
. . N

DESIGN/INTERVENTION VB N
A NNP N
statewide JJ N
survey NN N
of IN N
all DT N
primary JJ N
care NN N
clinicians NNS N
serving VBG N
children NNS N
addressed VBD N
their PRP N
self-reported JJ N
sun NN N
protection NN N
advocacy NN N
practices NNS N
. . N

Patient-reported JJ N
outcomes NNS N
after IN N
inguinal JJ N
herniorrhaphy NN N
. . N

[ JJ N
Intra-arterial JJ N
chemotherapy NN i
in IN N
advanced JJ N
ovarian JJ N
cancers NNS N
. . N

Group NNP N
1 CD N
received VBD N
100 CD N
mg NNS N
pethidine VBP N
; : N
group NN N
2 CD N
, , N
100 CD N
mg NN N
tramadol NN N
, , N
intramuscularly RB N
. . N

CS NNP N
included VBD N
speech/language NN N
and CC N
occupational JJ N
therapy NN i
and CC N
public JJ N
education NN N
services NNS N
. . N

All DT N
participants NNS N
used VBN N
electronic JJ N
diaries NNS N
and CC N
heart NN N
rate NN N
monitors NNS N
to TO N
track VB N
exercise NN N
frequency NN N
, , N
duration NN N
, , N
and CC N
intensity NN N
. . N

RESULTS NNP N
During IN N
trial NN N
1 CD N
, , N
there EX N
was VBD N
a DT N
-0.6 JJ N
+/- JJ N
0.3 CD N
mmol JJ N
l-1 NN N
( ( N
mean JJ N
+/- NNP N
SE NNP N
) ) N
change NN N
in IN N
lactate NN N
. . N

All DT N
treatment NN N
groups NNS N
demonstrated VBD N
dramatic JJ N
and CC N
persistent JJ N
decreases NNS o
in IN N
cocaine NN N
use NN N
, , N
craving VBG N
for IN N
cocaine NN N
, , N
and CC N
psychiatric JJ N
symptoms NNS N
consequent NN N
to TO N
treatment NN N
. . N

Patients NNS N
received VBD N
oral JJ N
esomeprazole JJ N
40 CD N
mg NN N
( ( N
n JJ N
= NNP N
220 CD N
) ) N
or CC N
20 CD N
mg NN N
( ( N
n JJ N
= NNP N
226 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
229 CD N
) ) N
once RB N
daily JJ N
for IN N
4 CD N
wk NN N
. . N

2-Chloroprocaine JJ N
antagonism NN N
of IN N
epidural JJ N
morphine NN N
analgesia NN N
. . N

Those DT N
in IN N
groups NNS N
2 CD N
, , N
3 CD N
and CC N
4 CD N
( ( N
RDN1 NNP N
, , N
RDN2 NNP N
and CC N
RDN3 NNP N
) ) N
were VBD N
supplemented VBN N
with IN N
groundnut NNS N
cake VBP N
to TO N
provide VB N
RDN NNP N
levels NNS N
of IN N
14 CD N
, , N
18 CD N
and CC N
23 CD N
g NN N
RDN NNP N
kg ? N
digestible JJ N
organic JJ N
matter NN N
intake NN N
( ( N
DOMI NNP N
) ) N
or CC N
21 CD N
, , N
27 CD N
and CC N
35 CD N
g NN N
RDN NNP N
kg ? N
digestible JJ N
organic JJ N
matter NN N
apparently RB N
digested VBN N
in IN N
the DT N
rumen NNS N
( ( N
DOMR NNP N
) ) N
respectively RB N
along IN N
with IN N
FMS NNP N
. . N

Fentanyl NNP N
( ( N
15 CD N
, , N
30 CD N
, , N
60 CD N
micro NN N
g JJ N
kg-1 JJ N
hour-1 NN N
) ) N
or CC N
remifentanil NN N
( ( N
60 CD N
, , N
120 CD N
, , N
240 CD N
micro NN N
g JJ N
kg-1 JJ N
hour-1 NN N
) ) N
were VBD N
infused VBN N
intravenously RB N
into IN N
a DT N
previously RB N
cannulated VBN N
tail NN N
vein NN N
. . N

METHODS NNP N
Open NNP N
randomised VBD N
crossover NN N
study NN N
undertaken VBP N
between IN N
October NNP N
2014 CD N
and CC N
March NNP N
2015 CD N
at IN N
the DT N
University NNP N
of IN N
Birmingham NNP N
, , N
United NNP N
Kingdom NNP N
. . N

Analgesia NNP N
was VBD N
initiated VBN N
with IN N
intrathecal JJ N
bupivacaine NN N
0.25 CD N
% NN N
1 CD N
mL NN N
+ NNP N
sufentanil VBD N
5 CD N
microg NN N
in IN N
the DT N
combined JJ N
spinal-epidural JJ N
group NN N
( ( N
n JJ N
= NNP N
54 CD N
) ) N
, , N
and CC N
with IN N
bupivacaine JJ N
0.125 CD N
% NN N
+ JJ N
epinephrine NN N
2.5 CD N
microg NN N
mL NN N
( ( N
-1 NNP N
) ) N
+ VBD N
sufentanil $ N
7.5 CD N
microg NN N
in IN N
the DT N
epidural JJ N
group NN N
( ( N
n JJ N
= NNP N
59 CD N
) ) N
. . N

Angiotensin NNP N
converting VBG N
enzyme NN N
( ( N
ACE NNP N
) ) N
inhibitors NNS N
block VBP N
degradation NN N
of IN N
bradykinin NN N
and CC N
bradykinin NN N
stimulates NNS N
prostacyclin VBP N
production NN N
. . N

They PRP N
used VBD N
Kruskal-Wallis NNP N
and CC N
Mann-Whitney NNP N
U NNP N
tests NNS N
for IN N
between-group JJ N
comparison NN N
. . N

One CD N
hundred VBD N
eleven JJ N
patients NNS p
filled VBN N
out RP N
the DT N
post NN N
questionnaire NN N
at IN N
4 CD N
weeks NNS N
. . N

STUDY NNP N
Patients NNPS N
were VBD N
randomly RB N
divided VBN N
into IN N
group NN N
A NNP N
( ( N
treated VBN N
with IN N
hepatectomy JJ N
alone RB N
) ) N
and CC N
group NN N
B NNP N
( ( N
underwent JJ N
hepatectomy NN N
combined VBN N
with IN N
lymphadenectomy NN N
) ) N
. . N

Twenty CD N
patients NNS p
were VBD N
treated VBN N
with IN N
oral JJ N
azithromycin NN i
, , N
250 CD N
mg NN N
bd NN N
for IN N
two CD N
days NNS N
followed VBN N
by IN N
250 CD N
mg NNS N
od NN N
for IN N
eight CD N
days NNS N
, , N
21 CD N
patients NNS p
were VBD N
given VBN N
phenoxymethylpenicillin $ i
1 CD N
million CD N
IU NNP N
tds NN N
for IN N
14 CD N
days NNS N
and CC N
23 CD N
patients NNS p
received JJ N
doxycycline NN N
, , N
100 CD N
mg NN N
bd NN N
for IN N
14 CD N
days NNS N
. . N

HCV NNP N
RNA NNP N
was VBD N
determined VBN N
at IN N
weeks NNS N
0 CD N
, , N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
8 CD N
and CC N
12 CD N
. . N

FINDINGS NNP N
Between NNP N
Oct NNP N
26 CD N
, , N
2012 CD N
, , N
and CC N
Feb NNP N
12 CD N
, , N
2014 CD N
, , N
2546 CD N
patients NNS p
were VBD N
eligible JJ N
to TO N
participate VB N
in IN N
the DT N
study NN N
. . N

Medication NNP N
was VBD N
administered VBN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
cross-over NN N
study NN N
. . N

The DT N
SAP NNP N
in IN N
groups NNS N
1 CD N
, , N
2 CD N
and CC N
3 CD N
was VBD N
178 CD N
+/- JJ N
55 CD N
, , N
123 CD N
+/- JJ N
24 CD N
and CC N
153 CD N
+/- JJ N
63 CD N
seconds NNS N
, , N
respectively RB N
. . N

The DT N
2 CD N
interventions NNS N
were VBD N
acceptable JJ N
to TO N
participants NNS N
and CC N
equal JJ N
with IN N
regard NN N
to TO N
perceived VBN N
credibility NN N
and CC N
acceptability NN N
. . N

Afatinib NNP N
versus NN N
cisplatin-based JJ N
chemotherapy NN i
for IN N
EGFR NNP N
mutation-positive JJ N
lung NN N
adenocarcinoma NN N
( ( N
LUX-Lung JJ N
3 CD N
and CC N
LUX-Lung NNP N
6 CD N
) ) N
: : N
analysis NN N
of IN N
overall JJ i
survival NN N
data NNS N
from IN N
two CD N
randomised VBD N
, , N
phase NN N
3 CD N
trials NNS N
. . N

Subjects NNS N
were VBD N
155 CD N
young JJ N
( ( N
aged VBN N
18-30 CD N
y NN N
) ) N
, , N
healthy JJ N
, , N
normal-weight JJ N
women NNS N
with IN N
intake NN N
of IN N
dietary JJ N
calcium NN N
< VBZ N
800 CD N
mg/d NN N
and CC N
energy NN N
intake VBP N
< CD N
/= JJ N
2200 CD N
kcal/d NN N
. . N

Thirty-seven JJ N
platinum-resistant JJ N
and CC N
27 CD N
platinum-sensitive JJ N
tumours NNS N
were VBD N
treated VBN N
with IN N
carboplatin NN i
or CC N
cisplatin NN i
as IN N
second-line JJ N
therapy NN i
. . N

Group NNP N
3 CD N
received VBD N
propofol JJ N
2 CD N
mg/kg NN N
i.v . N
, , N
followed VBN N
by IN N
propofol NN N
50 CD N
to TO N
160 CD N
micrograms/kg/min NN N
i.v NN N
. . N

Patients NNS N
randomised VBD N
to TO N
arm VB N
A NNP N
were VBD N
given VBN N
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
cytarabine NN N
on IN N
day NN N
1 CD N
preceding NN N
for IN N
6 CD N
h NN N
cisplatin NN i
infusion NN N
, , N
30 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/24 NN N
h NN N
cisplatin NN i
intravenous JJ N
( ( N
i.v JJ N
. . N

Obesity NNP N
( ( N
BMI NNP N
> VBZ N
30 CD N
kg/m NN N
( ( N
2 CD N
) ) N
) ) N
was VBD N
associated VBN N
with IN N
reduced JJ N
odds NNS N
( ( N
OR NNP N
= VBZ N
0.67 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.62-0.72 NN N
) ) N
. . N

Thus RB N
, , N
krill-oil JJ N
supplementation NN N
in IN N
overweight JJ N
adults NNS N
could MD N
exacerbate VB N
risk NN N
of IN N
diabetes NNS N
and CC N
cardiovascular JJ N
disease NN N
. . N

2 CD N
, , N
heifers NNS N
grazed VBD N
dormant JJ N
pasture NN N
and CC N
were VBD N
fed VBN N
0.9 CD N
kg NNS N
( ( N
as-fed JJ N
basis NN N
) ) N
of IN N
a DT N
42 CD N
% NN N
CP NNP N
supplement/d NN N
from IN N
weaning VBG N
in IN N
October NNP N
to TO N
late VB N
February NNP N
; : N
then RB N
heifers NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
treatments NNS N
for IN N
60 CD N
d NN N
before IN N
the DT N
breeding NN N
season NN N
. . N

The DT N
volunteer NN N
study NN N
was VBD N
a DT N
double-blind JJ N
cross-over JJ N
trial NN N
with IN N
10 CD N
volunteers NNS N
. . N

The DT N
proportion NN N
of IN N
vaccine NN N
high JJ N
responders NNS N
was VBD N
higher RBR N
in IN N
the DT N
experimental JJ N
group NN N
( ( N
n JJ N
= NNP N
48 CD N
) ) N
than IN N
among IN N
controls NNS N
( ( N
n JJ N
= VBZ N
49 CD N
; : N
48.8 CD N
% NN N
vs JJ N
25.0 CD N
% NN N
; : N
P NNP N
= NNP N
.02 NNP N
) ) N
at IN N
9 CD N
months NNS N
. . N

Early JJ N
remission NN N
does VBZ N
not RB N
preclude VB N
the DT N
need NN N
for IN N
ongoing VBG N
monitoring NN N
. . N

Regression NN N
of IN N
left JJ N
ventricular JJ N
hypertrophy NN N
after IN N
stentless JJ N
versus JJ N
conventional JJ N
aortic JJ N
valve NN N
replacement NN N
. . N

Thirteen NNP N
of IN N
the DT N
18 CD N
( ( N
72 CD N
% NN N
) ) N
women NNS N
who WP N
were VBD N
allocated VBN N
to TO N
receive VB N
the DT N
intervention NN N
completed VBD N
9 CD N
or CC N
more JJR N
sessions NNS N
of IN N
CBT NNP N
before IN N
the DT N
end NN N
of IN N
pregnancy NN N
. . N

METHODS NNP N
In IN N
this DT N
Phase NNP N
1 CD N
, , N
randomized VBN N
, , N
doubleblind VB N
, , N
placebo- JJ N
and CC N
active-controlled JJ N
, , N
3-arm JJ N
, , N
parallel JJ N
, , N
single-center JJ N
study NN N
, , N
healthy JJ N
subjects NNS N
received VBD N
placebo NN N
; : N
moxifloxacin CC i
400 CD N
mg NN N
; : N
or CC N
vilazodone NN i
( ( N
sequentially RB N
escalated VBN N
every DT N
3 CD N
days NNS N
) ) N
10 CD N
, , N
20 CD N
, , N
40 CD N
, , N
60 CD N
, , N
and CC N
80 CD N
mg/day NN N
. . N

This DT N
difference NN N
was VBD N
significant JJ N
( ( N
p JJ N
= NNP N
0.017 CD N
) ) N
. . N

Settings NNP N
included VBD N
an DT N
autism NN N
clinic NN N
and CC N
6 CD N
community-based JJ N
early JJ N
intervention NN N
programs NNS N
that WDT N
primarily RB N
serve VBP N
low-income JJ N
families NNS N
. . N

METHODS NNP N
In IN N
155 CD N
patients NNS p
with IN N
inferolateral JJ N
zone NN N
MI NNP N
, , N
as IN N
detected VBN N
by IN N
CE-CMR NNP N
, , N
the DT N
following JJ N
ECG NNP N
parameters NNS N
were VBD N
evaluated VBN N
and CC N
correlated VBN N
with IN N
MI NNP N
location NN N
according VBG N
to TO N
CE-CMR NN N
: : N
R/S NNP N
ratio NN N
in IN N
V1 NNP N
? . N
1 CD N
( ( N
classic JJ N
criteria NNS N
for IN N
posterior JJ N
MI NNP N
) ) N
, , N
R/S NNP N
ratio NN N
in IN N
V1 NNP N
? . N
0.5 CD N
, , N
and CC N
R NNP N
in IN N
V1 NNP N
? . N
3 CD N
mm NN N
. . N

Escalated VBN N
BEACOPP NNP N
uses VBZ N
higher JJR N
doses NNS N
of IN N
cyclophosphamide NN N
, , N
doxorubicin NN i
, , N
and CC N
etoposide RB N
with IN N
granulocyte JJ N
colony-stimulating JJ N
factor NN N
( ( N
G-CSF NNP N
) ) N
support NN N
. . N

Free JJ N
radicals NNS N
were VBD N
measured VBN N
using VBG N
electron NN N
spin NN N
resonance NN N
spectroscopy NN N
. . N

Melatonin NNP N
is VBZ N
known VBN N
for IN N
its PRP N
regulation NN N
of IN N
circadian JJ N
rhythm NN N
. . N

The DT N
patients NNS p
in IN N
the DT N
control NN N
group NN N
received VBD N
an DT N
equivalent JJ N
volume NN N
of IN N
normal JJ N
saline NN N
. . N

In IN N
the DT N
PointBreak NNP N
trial NN N
( ( N
pemetrexed-carboplatin-bevacizumab JJ i
and CC N
maintenance JJ N
pemetrexed-bevacizumab JJ i
[ NN N
PemCBev NNP N
] NNP N
vs . N
paclitaxel-carboplatin-bevacizumab NN i
and CC N
maintenance NN N
bevacizumab NN i
[ NNP N
PacCBev NNP N
] NNP N
) ) N
, , N
10 CD N
% NN N
of IN N
the DT N
patients NNS p
were VBD N
African JJ N
American NNP N
. . N

6 CD N
% NN N
( ( N
149 CD N
of IN N
2065 CD N
) ) N
and CC N
4 CD N
% NN N
( ( N
108 CD N
of IN N
2633 CD N
) ) N
of IN N
those DT N
in IN N
the DT N
pioglitazone NN N
and CC N
placebo NN N
groups NNS N
, , N
respectively RB N
, , N
were VBD N
admitted VBN N
to TO N
hospital VB N
with IN N
heart NN N
failure NN N
; : N
mortality NN N
rates NNS N
from IN N
heart NN N
failure NN N
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

Control NN N
of IN N
perioperative JJ N
hypertension NN N
during IN N
coronary JJ N
artery NN N
surgery NN N
. . N

Recruitment NN N
and CC N
Reasons NNP N
for IN N
Non-Participation NNP N
in IN N
a DT N
Family-Coping-Orientated JJ N
Palliative NNP N
Home NNP N
Care NNP N
Trial NNP N
( ( N
FamCope NNP N
) ) N
. . N

After IN N
a DT N
2-wk JJ N
run-in JJ N
period NN N
, , N
the DT N
doses NNS N
of IN N
BDI NNP N
were VBD N
halved VBN N
, , N
while IN N
the DT N
patients NNS p
were VBD N
assigned VBN N
to TO N
receive VB N
orally RB N
ONO-1078 NNP N
, , N
450 CD N
mg NN N
twice RB N
daily RB N
, , N
or CC N
placebo NN N
. . N

Among IN N
patients NNS p
on IN N
vitamin NN N
A NN N
for IN N
at IN N
least JJS N
2 CD N
years NNS N
, , N
a DT N
diet JJ N
rich JJ N
in IN N
omega-3 JJ N
fatty JJ N
acids NNS N
( ( N
> CD N
or CC N
=0.20 VB N
g/d NN N
) ) N
slowed VBD N
the DT N
decline NN N
in IN N
visual JJ N
field NN N
sensitivity NN N
. . N

Processing VBG N
familiar JJ N
and CC N
unfamiliar JJ N
auditory NN N
stimuli NN N
during IN N
general JJ N
anesthesia NN N
. . N

The DT N
EC50 NNP N
+/- JJ N
SE NNP N
values NNS N
in IN N
the DT N
Control NNP N
, , N
2.5 CD N
microg/kg NN N
Clonidine NNP N
, , N
and CC N
5.0 CD N
microg/kg NNS N
Clonidine NNP N
groups NNS N
were VBD N
2.67 CD N
+/- JJ N
0.18 CD N
, , N
1.31 CD N
+/- JJ N
0.12 CD N
, , N
and CC N
0.91 CD N
+/- JJ N
0.13 CD N
microg/mL NN N
, , N
respectively RB N
. . N

Endotracheal NNP N
cuff NN N
pressure NN N
and CC N
tracheal NN N
mucosal NN N
blood NN N
flow NN N
: : N
endoscopic NN N
study NN N
of IN N
effects NNS N
of IN N
four CD N
large JJ N
volume NN N
cuffs NNS N
. . N

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
phase NN N
3 CD N
trial NN N
conducted VBN N
from IN N
July NNP N
1997 CD N
through IN N
May NNP N
1999 CD N
. . N

A DT N
2,000-m JJ N
rowing NN N
time NN N
trial NN N
( ( N
TT NNP N
) ) N
was VBD N
performed VBN N
before IN N
supplementation NN N
( ( N
Baseline NNP N
) ) N
and CC N
after IN N
28 CD N
and CC N
30 CD N
days NNS N
of IN N
supplementation NN N
. . N

Spinal NNP N
anaesthesia NN N
was VBD N
performed VBN N
at IN N
L3-4 NNP N
or CC N
L4-5 NNP N
interspace NN N
with IN N
12.5 CD N
mg NNS N
0.5 CD N
% NN N
heavy JJ N
bupivacaine NN N
, , N
using VBG N
a DT N
25 CD N
G NNP N
Quincke NNP N
needle NN N
. . N

All DT N
teeth NNS N
were VBD N
fully RB N
covered VBN N
with IN N
polycarbonate JJ N
resin NN N
crowns NNS N
. . N

Moreover RB N
, , N
BW NNP N
decreased VBD o
both DT o
linearly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
quadratically RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
as IN N
choline NN N
increased VBN o
from IN N
0 CD N
to TO N
6,800 CD N
mg/kg NNS N
. . N

Sensitivity NN N
for IN N
recognition NN N
of IN N
myocardial JJ N
ischemia NN N
was VBD N
94 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
70 CD N
% NN N
to TO N
100 CD N
% NN N
) ) N
and CC N
88 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
62 CD N
% NN N
to TO N
98 CD N
% NN N
) ) N
, , N
respectively RB N
. . N

We PRP N
interviewed VBD N
study NN N
participants NNS N
every DT N
4 CD N
months NNS N
for IN N
2 CD N
years NNS N
to TO N
assess VB N
psychiatric JJ N
symptoms NNS N
and CC N
functional JJ N
status NN N
, , N
and CC N
we PRP N
collected VBD N
continuous JJ N
measures NNS N
of IN N
prescribed JJ N
medications NNS N
, , N
service NN N
utilization NN N
, , N
and CC N
other JJ N
costs NNS N
. . N

Multicomponent NNP N
interdisciplinary JJ N
group NN N
intervention NN N
for IN N
self-management NN N
of IN N
fibromyalgia NN N
: : N
a DT N
mixed-methods NNS N
randomized VBN N
controlled JJ N
trial NN N
. . N

SETTING NN N
Outpatient JJ N
clinics NNS N
. . N

The DT N
groups NNS N
were VBD N
: : N
( ( N
1 CD N
) ) N
the DT N
LED NNP N
group NN N
( ( N
treadmill IN N
training VBG N
associated VBN N
with IN N
phototherapy NN i
, , N
n JJ N
= NNP N
10 CD N
) ) N
, , N
( ( N
2 CD N
) ) N
the DT N
exercise NN N
group NN N
( ( N
treadmill IN N
training NN N
, , N
n JJ N
= NNP N
10 CD N
) ) N
, , N
and CC N
( ( N
3 CD N
) ) N
the DT N
sedentary JJ N
group NN N
( ( N
neither DT N
physical JJ N
training NN N
nor CC N
phototherapy NN i
, , N
n JJ N
= NNP N
10 CD N
) ) N
. . N

Herpes NNP N
simplex JJ N
virus NN N
vaccine NN N
in IN N
recurrent JJ N
herpetic JJ N
ocular JJ N
infection NN N
. . N

Skin NNP N
antisepsis NN N
with IN N
chlorhexidine-alcohol JJ N
versus NN N
povidone NN i
iodine-alcohol NN N
, , N
with IN N
and CC N
without IN N
skin JJ N
scrubbing NN N
, , N
for IN N
prevention NN N
of IN N
intravascular-catheter-related JJ N
infection NN N
( ( N
CLEAN NNP N
) ) N
: : N
an DT N
open-label JJ N
, , N
multicentre NN N
, , N
randomised VBN N
, , N
controlled VBN N
, , N
two-by-two JJ N
factorial JJ N
trial NN N
. . N

High JJ N
density NN N
lipoprotein VBP N
cholesterol NN N
remained VBD N
unchanged JJ N
. . N

The DT N
maximal JJ N
plasma NN N
concentration NN N
( ( N
Cmax NNP i
) ) N
of IN N
ropivacaine NN N
and CC N
bupivacaine NN N
were VBD N
964 CD N
( ( N
282 CD N
) ) N
ng NN N
ml NN N
( ( N
-1 NNP N
) ) N
and CC N
638 CD N
( ( N
366 CD N
) ) N
ng NN N
ml NN N
( ( N
-1 NNP N
) ) N
, , N
respectively RB N
. . N

Depressive JJ N
symptoms NNS N
were VBD N
assessed VBN N
by IN N
the DT N
Children NNP N
's POS N
Depression NNP N
Inventory NNP N
( ( N
CDI NNP N
) ) N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
cost NN N
effectiveness NN N
of IN N
CSF NNP N
. . N

Validity NNP N
and CC N
reliability NN N
assessment NN N
of IN N
the DT N
Siriraj NNP N
Asthma NNP N
Control NNP N
Questionnaire NNP N
. . N

RCT NNP N
of IN N
a DT N
manualized JJ N
social JJ N
treatment NN N
for IN N
high-functioning JJ N
autism NN N
spectrum NN N
disorders NNS N
. . N

The DT N
Social NNP N
Communication NNP N
Assessment NNP N
for IN N
Toddlers NNP N
with IN N
Autism NNP N
( ( N
SCATA NNP N
) ) N
was VBD N
designed VBN N
to TO N
measure VB N
non-verbal JJ N
communication NN N
, , N
including VBG N
early JJ N
and CC N
atypical JJ N
communication NN N
, , N
in IN N
young JJ N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
. . N

After IN N
receiving VBG N
an DT N
educational JJ N
leaflet NN N
, , N
young JJ N
post-menopausal JJ N
women NNS N
suffering VBG N
osteoporosis NN N
did VBD N
not RB N
show VB N
improvement NN N
in IN N
adherence NN N
to TO N
therapy VB i
. . N

Chronic NNP N
disease NN N
prevalence NN N
and CC N
severity NN N
, , N
preadmission NN N
functional JJ N
status NN N
, , N
clinical JJ N
presentation NN N
, , N
and CC N
vascular JJ N
history NN N
were VBD N
used VBN N
to TO N
test VB N
the DT N
risk-adjusted JJ N
effect NN N
of IN N
race NN N
and CC N
ethnicity NN N
on IN N
rates NNS N
of IN N
primary JJ N
and CC N
repeat JJ N
amputation NN N
. . N

Effects NNS N
of IN N
weight JJ N
loss NN N
and CC N
exercise NN N
on IN N
insulin NN N
resistance NN N
, , N
and CC N
intramyocellular JJ N
triacylglycerol NN N
, , N
diacylglycerol NN N
and CC N
ceramide NN N
. . N

Recatheterization NN N
and CC N
submaximal JJ N
exercise NN N
thallium-201 JJ N
single JJ N
photon NN N
emission NN N
computed VBD N
tomography NN N
were VBD N
performed VBN N
before IN N
hospital JJ N
discharge NN N
. . N

In IN N
the DT N
first JJ N
condition NN N
intervals NNS N
were VBD N
produced VBN N
by IN N
finger NN N
tapping NN N
, , N
and CC N
in IN N
the DT N
second JJ N
by IN N
an DT N
oscillatory JJ N
motion NN N
of IN N
the DT N
hand NN N
. . N

Those DT N
with IN N
diet-related JJ N
CRC NNP N
prevention NN N
beliefs NNS N
had VBD N
healthier JJR N
intakes NNS N
for IN N
dietary JJ N
fiber NN N
( ( N
p JJ N
= NNP N
.005 NNP N
) ) N
, , N
fruit NN N
, , N
vegetable NN N
, , N
bean NN N
( ( N
p JJ N
= NNP N
.027 NNP N
) ) N
, , N
red JJ N
meat NN N
( ( N
p JJ N
= NNP N
.032 NNP N
) ) N
, , N
vitamin FW N
C NNP N
( ( N
p JJ N
= NNP N
.039 NNP N
) ) N
, , N
and CC N
cholesterol NN N
( ( N
p JJ N
= NNP N
.045 NNP N
) ) N
. . N

In IN N
Experiment JJ N
1 CD N
, , N
a DT N
series NN N
of IN N
prime-target JJ N
pairs NNS N
was VBD N
presented VBN N
auditorily RB N
, , N
and CC N
participants NNS N
were VBD N
asked VBN N
to TO N
make VB N
a DT N
lexical JJ N
decision NN N
on IN N
the DT N
target NN N
word NN N
. . N

Ten CD N
active JJ N
female JJ N
subjects NNS N
participated VBD N
( ( N
32 CD N
+/- JJ N
7 CD N
yrs NN N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
; : N
65.7 CD N
+/- JJ N
16.4 CD N
kg NN N
; : N
VO2peak NNP N
40.0 CD N
+/- JJ N
7.5 CD N
ml.kg-1.min-1 NN N
) ) N
. . N

Autologous JJ N
cytokine-induced JJ N
killer NN N
( ( N
CIK NNP N
) ) N
cells NNS N
were VBD N
transfused VBN N
via IN N
hepatic JJ N
artery NN N
to TO N
the DT N
patients NNS p
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
. . N

In IN N
the DT N
multicentre NN N
prospective JJ N
randomized VBN N
HD2002 NNP N
trial NN N
, , N
rituximab JJ i
maintenance NN N
therapy NN i
( ( N
375 CD N
mg/m NN N
( ( N
2 CD N
) ) N
every DT N
3 CD N
months NNS N
for IN N
2 CD N
years NNS N
) ) N
versus VBP N
observation NN N
was VBD N
evaluated VBN N
for IN N
CD20 NNP N
( ( N
+ NNP N
) ) N
B-cell NNP N
lymphoma NN N
. . N

Long-term JJ N
( ( N
96-week JJ N
) ) N
follow-up NN N
of IN N
antiretroviral-na ? N
HIV-infected JJ N
patients NNS p
treated VBN N
with IN N
first-line JJ N
lopinavir/ritonavir NN N
monotherapy NN i
in IN N
the DT N
MONARK NNP N
trial NN N
. . N

DESIGN NNP N
Randomized NNP N
, , N
single-blinded JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

Spinal NNP N
cord NN N
excitability NN N
was VBD N
investigated VBN N
by IN N
distal JJ N
latencies NNS N
and CC N
M-amplitudes NNS N
of IN N
the DT N
abductor NN N
digiti NN N
minimi NN N
muscle NN N
. . N

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
or CC N
wait-list JJ N
conditions NNS N
. . N

MAIN NNP N
RESULTS NNP N
Of IN N
132 CD N
eligible JJ N
patients NNS p
, , N
113 CD N
were VBD N
randomized VBN N
. . N

Conditional NNP N
logistic JJ N
regression NN N
was VBD N
used VBN N
to TO N
estimate VB N
adjusted VBN N
odds NNS N
ratios NNS N
( ( N
OR NNP N
) ) N
and CC N
95 CD N
% NN N
CI NNP N
. . N

Thus RB N
, , N
VEGF/VEGFR-2 NNP N
might MD N
constitute VB N
promising VBG N
targets NNS N
for IN N
antiangiogenic JJ N
and CC N
antileukemic JJ N
treatment NN N
strategies NNS N
in IN N
AML NNP N
. . N

The DT N
participants NNS N
reported VBD N
their PRP N
daily JJ N
emotional JJ N
experiences NNS N
, , N
by IN N
completing VBG N
questionnaires NNS N
relating VBG N
to TO N
sensory JJ N
and CC N
social JJ N
pleasure NN N
. . N

Both CC N
the DT N
feasibility NN N
studies NNS N
and CC N
the DT N
usability NN N
testing VBG N
highlighted VBD N
the DT N
need NN N
to TO N
address VB N
men NNS N
's POS N
informed VBN N
decision NN N
making VBG N
regarding VBG N
screening NN N
. . N

Since IN N
there EX N
are VBP N
no DT N
uniformly RB N
accepted VBN N
guidelines NNS N
for IN N
the DT N
modification NN N
of IN N
antibiotic JJ i
therapy NN i
during IN N
the DT N
post-empiric JJ N
phase NN N
, , N
we PRP N
assessed VBD N
the DT N
impact NN N
of IN N
a DT N
set NN N
of IN N
rules NNS N
that WDT N
evolved VBD N
during IN N
the DT N
first JJ N
randomized JJ N
trials NNS N
. . N

Profound NNP N
luteinizing VBG N
hormone NN N
suppression NN N
after IN N
stopping VBG N
the DT N
gonadotropin-releasing JJ N
hormone-agonist JJ N
leuprolide NN N
acetate NN N
. . N

METHODS NNP N
Before IN N
sitaxsentan NN N
withdrawal NN N
, , N
this DT N
18-week JJ N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
randomized VBD N
patients NNS p
with IN N
PAH NNP N
to TO N
receive VB N
placebo NN N
or CC N
sitaxsentan VB N
50 CD N
or CC N
100 CD N
mg NNS N
once RB N
daily RB N
. . N

Patients NNS N
were VBD N
evaluated VBN N
by IN N
the DT N
American JJ N
Orthopaedic NNP N
Foot NNP N
and CC N
Ankle NNP N
Society NNP N
( ( N
AOFAS NNP N
) ) N
Ankle-Hindfoot NNP N
Scale NNP N
and CC N
followed-up NN N
after IN N
12 CD N
months NNS N
. . N

Randomized NNP N
clinical JJ N
trial NN N
of IN N
cutting VBG N
balloon NN N
angioplasty JJ N
versus NN N
high-pressure NN N
balloon NN N
angioplasty NN N
in IN N
hemodialysis NN N
arteriovenous JJ N
fistula NN N
stenoses VBZ N
resistant JJ N
to TO N
conventional JJ N
balloon NN N
angioplasty NN N
. . N

Stapled VBN N
hemorrhoidopexy NN N
vs. FW N
Harmonic NNP N
Scalpel NNP N
hemorrhoidectomy NN N
: : N
a DT N
randomized JJ N
trial NN N
. . N

This DT N
effect NN N
was VBD N
more RBR N
pronounced JJ N
in IN N
whites NNS N
( ( N
-4.1 JJ N
ng/mL NN N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
) ) N
compared VBN N
with IN N
African-Americans NNP N
( ( N
-0.3 JJ N
ng/mL NN N
( ( N
P NNP N
= NNP N
0.7 CD N
) ) N
, , N
P-interaction NNP N
= NNP N
0.03 CD N
) ) N
. . N

Subjects NNS N
treated VBD N
with IN N
glargine NN N
had VBD N
greater JJR N
reductions NNS N
of IN N
HbA1c NNP N
[ NNP N
-1.94 NNP N
% NN N
( ( N
0.05 CD N
) ) N
and CC N
-1.79 $ N
% NN N
( ( N
0.05 CD N
) ) N
; : N
p CC N
= $ N
0.019 CD N
] NN N
and CC N
fasting VBG N
plasma NN N
glucose JJ N
[ JJ N
6.2 CD N
( ( N
1.6 CD N
) ) N
and CC N
7.9 CD N
( ( N
2.2 CD N
) ) N
mmol/L NN N
; : N
p CC N
< $ N
0.001 CD N
] NN N
than IN N
those DT N
receiving VBG N
liraglutide RB N
. . N

INTERPRETATION NNP N
EVAR NNP N
had VBD N
a DT N
considerable JJ N
30-day JJ N
operative JJ N
mortality NN N
in IN N
patients NNS p
already RB N
unfit JJ N
for IN N
open JJ N
repair NN N
of IN N
their PRP N
aneurysm NN N
. . N

Cohort NNP N
2 CD N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
was VBD N
treated VBN N
every DT N
2 CD N
weeks NNS N
, , N
with IN N
leukapheresis NN N
on IN N
day NN N
1 CD N
of IN N
the DT N
next JJ N
cycle NN N
and CC N
storage NN N
of IN N
the DT N
leukapheresis NN N
product NN N
at IN N
4 CD N
degrees NNS N
C. NNP N
Cohort NNP N
3 CD N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
was VBD N
treated VBN N
every DT N
2 CD N
weeks NNS N
, , N
with IN N
500 CD N
to TO N
750 CD N
mL NNS N
of IN N
blood NN N
drawn VBN N
by IN N
venesection NN N
on IN N
day NN N
1 CD N
of IN N
the DT N
next JJ N
cycle NN N
and CC N
stored VBD N
at IN N
4 CD N
degrees NNS N
C. NNP N
In IN N
cohorts NNS N
2 CD N
and CC N
3 CD N
, , N
chemotherapy NN i
was VBD N
given VBN N
if IN N
the DT N
WBC NNP N
count NN N
was VBD N
> JJ N
or CC N
= JJ N
3 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
and CC N
platelet NN N
count NN N
> NNP N
or CC N
= $ N
30 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
. . N

Pars NNS N
plana VBP N
vitrectomy NN N
for IN N
diabetic JJ N
macular JJ N
edema NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
levosulpiride NN N
( ( N
25 CD N
mg RB N
tid NN N
) ) N
, , N
domperidone NN i
( ( N
10 CD N
mg RB N
tid NN N
) ) N
, , N
metoclopramide RB N
( ( N
10 CD N
mg RB N
tid NN N
) ) N
or CC N
placebo NN N
( ( N
1 CD N
tablet NN N
tid NN N
) ) N
for IN N
4 CD N
weeks NNS N
. . N

BP NNP N
control NN N
was VBD N
defined VBN N
as IN N
systolic JJ N
BP NNP N
< NNP N
140 CD N
mm NN N
Hg NNP N
and CC N
diastolic JJ N
BP NNP N
< NNP N
90 CD N
mm NN N
Hg NNP N
. . N

Blood NNP N
and CC N
sputum NN N
eosinophils NNS N
and CC N
serum NN N
levels NNS N
of IN N
eosinophil NN N
cationic JJ N
protein NN N
( ( N
ECP NNP N
) ) N
and CC N
intercellular JJ N
adhesion NN N
molecule-1 NN N
( ( N
ICAM-1 NNP N
) ) N
were VBD N
measured VBN N
. . N

BACKGROUND NNP N
Patients NNPS N
with IN N
type JJ N
2 CD N
diabetes NNS N
are VBP N
at IN N
high JJ N
risk NN N
of IN N
fatal JJ N
and CC N
non-fatal JJ N
myocardial JJ N
infarction NN N
and CC N
stroke NN N
. . N

In IN N
the DT N
subgroup NN N
analysis NN N
of IN N
patients NNS p
who WP N
had VBD N
valve NN N
reoperations NNS N
, , N
lower JJR N
blood NN N
transfusion NN N
requirements NNS N
in IN N
the DT N
intensive JJ N
care NN N
unit NN N
( ( N
p JJ N
= NNP N
0.013 CD N
) ) N
were VBD N
found VBN N
in IN N
the DT N
study NN N
group NN N
. . N

The DT N
mean JJ N
copy NN N
numbers NNS N
+/- JJ N
SE NNP N
of IN N
mean NN N
( ( N
SEM NNP N
) ) N
of IN N
HSV-1 NNP N
DNA NNP N
in IN N
tears NNS N
were VBD N
340 CD N
+/- JJ N
35 CD N
, , N
1074 CD N
+/- JJ N
320 CD N
, , N
and CC N
630 CD N
+/- JJ N
51 CD N
for IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
, , N
and CC N
in IN N
saliva NN N
were VBD N
238 CD N
+/- JJ N
35 CD N
, , N
963 CD N
+/- JJ N
462 CD N
, , N
and CC N
493 CD N
+/- JJ N
25 CD N
, , N
respectively RB N
, , N
for IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
. . N

The DT N
two CD N
groups NNS N
were VBD N
comparable JJ N
at IN N
entry NN N
and CC N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
developed VBD N
at IN N
any DT N
time NN N
during IN N
the DT N
treatment NN N
period NN N
. . N

The DT N
parameters NNS N
studied VBN N
were VBD N
Superoxide NNP N
dismutase NN N
( ( N
SOD NNP N
) ) N
, , N
malonyl-dialdehyde JJ N
( ( N
MDA NNP N
) ) N
and CC N
reduced VBN N
glutathione NN N
( ( N
GSH NNP N
) ) N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
physical JJ N
therapy NN i
for IN N
osteoarthritis NN N
of IN N
the DT N
knee NN N
, , N
applied VBN N
by IN N
experienced JJ N
physical JJ N
therapists NNS N
with IN N
formal JJ N
training NN N
in IN N
manual JJ N
therapy NN i
. . N

In IN N
the DT N
single-dose JJ N
studies NNS N
, , N
a DT N
total NN N
of IN N
183 CD N
subjects NNS N
received VBD N
oral JJ N
doses NNS N
of IN N
bilastine NN N
2.5 CD N
, , N
5 CD N
, , N
10 CD N
, , N
20 CD N
, , N
50 CD N
, , N
100 CD N
, , N
120 CD N
, , N
160 CD N
, , N
200 CD N
and CC N
220 CD N
mg NN N
. . N

Heifers NNS N
treated VBD N
with IN N
SG+IVPO NNP N
consumed VBD N
more RBR N
DM NNP N
, , N
had VBD N
greater JJR N
ADG NNP N
, , N
were VBD N
heavier JJR N
at IN N
slaughter NN N
, , N
and CC N
had VBD N
heavier JJR N
carcasses NNS N
than IN N
IVPO-treated JJ N
heifers NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Effects NNS N
of IN N
20 CD N
mg NNS N
rosuvastatin NN i
on IN N
VLDL1- NNP N
, , N
VLDL2- NNP N
, , N
IDL- NNP N
and CC N
LDL-ApoB NNP N
kinetics NNS N
in IN N
type NN N
2 CD N
diabetes NNS N
. . N

For IN N
endoscopic JJ N
recurrence NN N
( ( N
Rutgeerts NNP N
score RB N
? i2 N
) ) N
at IN N
6 CD N
months NNS N
, , N
patients NNS p
stepped-up VBP N
to TO N
thiopurine VB N
, , N
fortnightly RB N
adalimumab VBZ i
with IN N
thiopurine NN N
, , N
or CC N
weekly JJ N
adalimumab NN i
. . N

OUTCOME NNP N
MEASURES NNP N
Thermodilution NNP N
cardiac NN N
output NN N
measurements NNS N
. . N

SBP NNP N
( ( N
175 CD N
+/- JJ N
3.3 CD N
vs. FW N
160 CD N
+/- JJ N
3.0 CD N
mm NN N
Hg NNP N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
DBP NNP N
( ( N
106 CD N
+/- JJ N
2.3 CD N
vs. FW N
95 CD N
+/- JJ N
2.0 CD N
mm NN N
Hg NNP N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
were VBD N
significantly RB N
reduced VBN N
by IN N
lisinopril JJ N
administration NN N
. . N

AUC NNP N
( ( N
0-150 JJ N
) ) N
of IN N
APAP/pl NNP N
is VBZ N
significantly RB N
different JJ N
from IN N
pl/pl NN N
( ( N
-3452 CD N
% NN N
.min NNP N
( ( N
95 CD N
% NN N
CI NNP N
-4705 NNP N
to TO N
-2199 VB N
) ) N
vs. FW N
-933 CD N
% NN N
min NN N
( ( N
95 CD N
% NN N
CI NNP N
-2273 NNP N
to TO N
407 CD N
; : N
P NNP N
= NNP N
0.015 CD N
) ) N
but CC N
not RB N
from IN N
APAP/Nal NNP N
( ( N
-1731 CD N
% NN N
min NN N
( ( N
95 CD N
% NN N
CI NNP N
-3676 NNP N
to TO N
214 CD N
; : N
P NNP N
= NNP N
0.08 CD N
) ) N
and CC N
other JJ N
treatments NNS N
. . N

Amplitude NNP N
changes NNS N
were VBD N
significant JJ N
for IN N
APAP/pl NNP N
vs. FW N
pl/pl NN N
at IN N
t150 NN N
: : N
-44 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-58 NNP N
to TO N
-30 VB N
) ) N
vs. FW N
-27 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-37 NNP N
to TO N
-17 VB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
but CC N
not RB N
vs . N
APAP/Nal NNP N
. . N

Matched VBN N
HR NNP N
for IN N
cardiovascular JJ N
and CC N
HF NNP N
hospitalization NN N
were VBD N
respectively RB N
1.17 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.06-1.28 JJ N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
and CC N
1.28 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.13-1.45 JJ N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Female JJ N
smokers NNS N
had VBD N
higher JJR N
serum JJ N
low-density NN N
lipoprotein NN N
( ( N
LDL NNP N
) ) N
/high-density NN N
lipoprotein NN N
( ( N
HDL NNP N
) ) N
ratios NNS N
and CC N
triglycerides NNS N
. . N

Clinical JJ N
signs NNS N
of IN N
severe JJ N
photodamage NN N
at IN N
baseline NN N
[ NNP N
odds NNS N
ratio NN N
( ( N
OR NNP N
) ) N
0 ? N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
0 ? N
] NN N
and CC N
history NN N
of IN N
acne NN N
( ( N
OR CC N
0 ? N
, , N
95 CD N
% NN N
CI NNP N
0 ? N
) ) N
were VBD N
associated VBN N
with IN N
a DT N
decreased JJ o
risk NN N
of IN N
adverse JJ N
effects NNS N
to TO N
tretinoin VB N
. . N

Greater NNP N
proportions NNS N
of IN N
high JJ N
responders NNS N
were VBD N
also RB N
observed VBN N
at IN N
3 CD N
( ( N
51.1 CD N
% NN N
vs JJ N
39.6 CD N
% NN N
; : N
P NNP N
= NNP N
.26 NNP N
) ) N
, , N
4 CD N
( ( N
77.3 CD N
% NN N
vs JJ N
56.3 CD N
% NN N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
, , N
and CC N
10 CD N
months NNS N
( ( N
87.8 CD N
% NN N
vs JJ N
51.1 CD N
% NN N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Baseline NNP N
leptin NN i
levels NNS N
( ( N
mean JJ N
+/- JJ N
SEM NN N
: : N
12.4 CD N
+/- JJ N
2.1 CD N
micrograms/L NN N
) ) N
were VBD N
independent JJ N
of IN N
body NN N
mass NN N
index NN N
( ( N
25 CD N
+/- JJ N
1 CD N
kg/m2 NN N
) ) N
, , N
insulin NN N
( ( N
18.6 CD N
+/- JJ N
2.9 CD N
microIU/mL NN N
) ) N
, , N
cortisol NN N
( ( N
504 CD N
+/- JJ N
43 CD N
mmol/L NN N
) ) N
, , N
and CC N
thyroid JJ N
hormones NNS N
( ( N
T4 NNP N
: : N
63 CD N
+/- JJ N
5 CD N
nmol/L NN N
, , N
T3 NNP N
: : N
0.72 CD N
+/- JJ N
0.08 CD N
nmol/L NN N
) ) N
but CC N
correlated VBD N
positively RB N
with IN N
circulating VBG N
levels NNS N
of IN N
IGF-I NNP N
[ NNP N
86 CD N
+/- JJ N
6 CD N
micrograms/L NN N
, , N
determination NN N
coefficient NN N
( ( N
R2 NNP N
) ) N
= VBD N
0.25 CD N
] NN N
and CC N
ALS NNP N
( ( N
7.2 CD N
+/- JJ N
0.6 CD N
mg/L NN N
, , N
R2 NNP N
= NNP N
0.32 CD N
) ) N
. . N

In IN N
multivariate NN N
analyses NNS N
, , N
greater JJR N
BMI NNP N
was VBD N
significantly RB N
associated VBN N
with IN N
higher JJR N
PCSM NNP N
( ( N
for IN N
BMI NNP N
> NNP N
or CC N
=25 VB N
to TO N
< VB N
30 CD N
, , N
hazard RB N
ratio NN N
[ NNP N
HR NNP N
] NNP N
1.52 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
1.02-2.27 JJ N
, , N
P NNP N
= NNP N
.04 NNP N
; : N
for IN N
BMI NNP N
> NNP N
or CC N
=30 NNP N
, , N
HR NNP N
1.64 CD N
, , N
95 CD N
% NN N
CI NNP N
, , N
1.01-2.66 JJ N
, , N
P NNP N
= NNP N
.04 NNP N
) ) N
. . N

Lung NNP N
compliance NN N
was VBD N
higher JJR N
5 CD N
minutes NNS N
before IN N
bypass NN N
in IN N
group NN N
1 CD N
versus NN N
group NN N
5 CD N
( ( N
34 CD N
+/- JJ N
13 CD N
mL/cm NN N
H NNP N
( ( N
2 CD N
) ) N
O NNP N
vs $ N
20 CD N
+/- JJ N
9 CD N
mL/cm NN N
H NNP N
( ( N
2 CD N
) ) N
O NNP N
; : N
P NNP N
= NNP N
0.048 CD N
) ) N
. . N

These DT N
findings NNS N
support VBP N
a DT N
potential JJ N
mechanism NN N
of IN N
action NN N
by IN N
showing VBG N
that IN N
NTX NNP N
reduced VBD N
cue-induced JJ N
craving NN N
and CC N
subjective JJ N
responses NNS N
to TO N
MA NNP N
. . N

Both DT N
active JJ N
treatments NNS N
were VBD N
also RB N
associated VBN N
with IN N
reduced JJ N
weekly JJ N
episodes NNS N
of IN N
urticaria NNS N
compared VBN N
with IN N
placebo NN N
, , N
which WDT N
was VBD N
significant JJ N
after IN N
2 CD N
weeks NNS N
' POS N
treatment NN N
( ( N
mizolastine NN N
: : N
7.9 CD N
episodes NNS N
, , N
P NNP N
= NNP N
0.0061 CD N
; : N
loratadine NN N
: : N
8.3 CD N
, , N
P NNP N
= NNP N
0.0221 CD N
; : N
placebo NN N
: : N
13.3 CD N
) ) N
. . N

Cardiac NNP N
function NN N
was VBD N
monitored VBN N
by IN N
multiple-gated JJ N
radionuclide NN N
cardioangiography NN N
scan JJ N
, , N
and CC N
the DT N
left JJ N
ventricular JJ N
ejection NN N
fraction NN N
( ( N
LVEF NNP N
) ) N
was VBD N
scored VBN N
at IN N
a DT N
central JJ N
laboratory NN N
. . N

In IN N
the DT N
FAM NNP N
arm NN N
there EX N
were VBD N
3 CD N
( ( N
18 CD N
% NN N
) ) N
responders NNS N
( ( N
2 CD N
CR NNP N
and CC N
1 CD N
PR NNP N
) ) N
, , N
7 CD N
( ( N
41 CD N
% NN N
) ) N
SD NNP N
and CC N
7 CD N
( ( N
41 CD N
% NN N
) ) N
PD NNP N
, , N
versus NN N
O NNP N
responders NNS N
, , N
5 CD N
( ( N
31 CD N
% NN N
) ) N
SD NNP N
and CC N
11 CD N
( ( N
69 CD N
% NN N
) ) N
PD NNP N
in IN N
the DT N
5-FU JJ N
plus CC N
BCNU NNP N
arm NN N
. . N

The DT N
most RBS N
frequent JJ N
grade NN N
3 CD N
or CC N
4 CD N
drug-related JJ N
adverse JJ N
events NNS N
were VBD N
rash JJ N
or CC N
acne NN N
( ( N
31 CD N
[ RB N
10 CD N
% NN N
] NN N
of IN N
320 CD N
patients NNS p
in IN N
the DT N
afatinib NN N
group NN N
vs VBD N
none NN N
of IN N
160 CD N
patients NNS p
in IN N
the DT N
methotrexate NN N
group NN N
) ) N
, , N
diarrhoea NN N
( ( N
30 CD N
[ RB N
9 CD N
% NN N
] NN N
vs NN N
three CD N
[ $ N
2 CD N
% NN N
] NN N
) ) N
, , N
stomatitis NN N
( ( N
20 CD N
[ RB N
6 CD N
% NN N
] NNP N
vs NN N
13 CD N
[ JJ N
8 CD N
% NN N
] NN N
) ) N
, , N
fatigue NN N
( ( N
18 CD N
[ RB N
6 CD N
% NN N
] JJ N
vs NN N
five CD N
[ JJ N
3 CD N
% NN N
] NN N
) ) N
, , N
and CC N
neutropenia NN N
( ( N
1 CD N
[ NNP N
< VBD N
1 CD N
% NN N
] NNP N
vs NN N
11 CD N
[ JJ N
7 CD N
% NN N
] NN N
) ) N
; : N
serious JJ N
adverse JJ N
events NNS N
occurred VBD N
in IN N
44 CD N
( ( N
14 CD N
% NN N
) ) N
of IN N
afatinib-treated JJ N
patients NNS p
and CC N
18 CD N
( ( N
11 CD N
% NN N
) ) N
of IN N
methotrexate-treated JJ N
patients NNS p
. . N

Median JJ N
progression-free JJ N
survival NN N
was VBD N
3.9 CD N
months NNS N
with IN N
pembrolizumab JJ i
2 CD N
mg/kg NN N
, , N
4.0 CD N
months NNS N
with IN N
pembrolizumab JJ i
10 CD N
mg/kg NN N
, , N
and CC N
4.0 CD N
months NNS N
with IN N
docetaxel NN i
, , N
with IN N
no DT N
significant JJ N
difference NN N
for IN N
pembrolizumab NN i
2 CD N
mg/kg NN N
versus NN N
docetaxel NN i
( ( N
0.88 CD N
, , N
0.74-1.05 CD N
; : N
p=0.07 NN N
) ) N
or CC N
for IN N
pembrolizumab JJ i
10 CD N
mg/kg NN N
versus NN N
docetaxel NN i
( ( N
HR NNP N
0.79 CD N
, , N
95 CD N
% NN N
CI NNP N
0.66-0.94 CD N
; : N
p=0.004 NN N
) ) N
. . N

Twenty CD N
patients NNS p
died VBD N
during IN N
the DT N
LTE NNP N
( ( N
n JJ N
= $ N
5 CD N
MI NNP N
; : N
n CC N
= $ N
9 CD N
LI NNP N
; : N
n CC N
= $ N
6 CD N
CsA NNP N
) ) N
, , N
and CC N
eight CD N
experienced VBD N
graft NN N
loss NN N
( ( N
n JJ N
= $ N
2 CD N
MI NNP N
; : N
n CC N
= $ N
1 CD N
LI NNP N
; : N
n CC N
= $ N
5 CD N
CsA NNP N
) ) N
. . N

The DT N
influence NN N
of IN N
rTMS NN N
over IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal JJ N
cortex NN N
on IN N
Stroop NNP N
task NN N
performance NN N
. . N

METHODS NNP N
Patients NNPS N
received VBD N
CDDP NNP N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
plus CC N
DCT NNP N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
on IN N
day NN N
1 CD N
every DT N
weeks NNS N
( ( N
arm IN N
A NNP N
) ) N
or CC N
CDDP $ N
80 CD N
mg/m NN N
( ( N
2 CD N
) ) N
on IN N
day NN N
1 CD N
plus CC N
VNR NNP N
30 CD N
mg/m NN N
( ( N
2 CD N
) ) N
day NN N
1 CD N
and CC N
8 CD N
every DT N
3 CD N
weeks NNS N
( ( N
arm NN N
B NNP N
) ) N
. . N

RESULTS NNP N
For IN N
the DT N
primary JJ N
end NN N
point NN N
, , N
mean JJ N
+/- JJ N
sd NN N
maximum JJ N
negative JJ N
intrathoracic NN N
pressures NNS N
( ( N
mm VB N
Hg NNP N
) ) N
during IN N
the DT N
decompression NN N
phase NN N
of IN N
cardiopulmonary JJ N
resuscitation NN N
were VBD N
-1.0 JJ N
+/- JJ N
0.73 CD N
mm NN N
Hg NNP N
with IN N
a DT N
sham NN N
vs. FW N
-4.6 NNP N
+/- JJ N
3.7 CD N
mm NN N
Hg NNP N
with IN N
an DT N
active JJ N
ITD NN N
on IN N
the DT N
facemask NN N
( ( N
p JJ N
= NNP N
.003 NNP N
) ) N
and CC N
-1.3 JJ N
+/- JJ N
1.3 CD N
mm NN N
Hg NNP N
with IN N
a DT N
sham NN N
ITD NNP N
vs . N
-7.3 NNP N
+/- JJ N
4.5 CD N
mm NN N
Hg NNP N
with IN N
an DT N
active JJ N
ITD NNP N
on IN N
an DT N
ETT NNP N
( ( N
p JJ N
= NNP N
.0009 NNP N
) ) N
. . N

Research NN N
participants NNS N
for IN N
the DT N
ESRA-C NNP N
study NN N
were VBD N
recruited VBN N
from IN N
the DT N
Seattle NNP N
Cancer NNP N
Care NNP N
Alliance NNP N
, , N
a DT N
consortium NN N
among IN N
the DT N
University NNP N
of IN N
Washington NNP N
Medical NNP N
Center NNP N
, , N
Fred NNP N
Hutchinson NNP N
Cancer NNP N
Research NNP N
Center NNP N
, , N
and CC N
Children NNP N
's POS N
Hospital NNP N
and CC N
Regional NNP N
Medical NNP N
Center NNP N
in IN N
Seattle NNP N
, , N
WA NNP N
. . N

Behavioral NNP N
rating NN N
scales NNS N
( ( N
Clinical JJ N
Global NNP N
Impression NNP N
Scale NNP N
[ NNP N
CGI-I NNP N
] NNP N
, , N
Ritvo-Freeman NNP N
Real NNP N
Life NNP N
Rating NNP N
Scale NNP N
[ NNP N
RF-RLRS NNP N
] NNP N
) ) N
, , N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
[ NNP N
ABC NNP N
] NNP N
, , N
Turgay NNP N
DSM-IV NNP N
Pervasive NNP N
Developmental NNP N
Disorder NNP N
Rating NNP N
Scale NNP N
[ NNP N
TPDDRS NNP N
] NNP N
) ) N
and CC N
safety NN N
assessment NN N
scales NNS N
( ( N
Extrapyramidal NNP N
Symptoms NNP N
Rating NNP N
Scale NNP N
[ NNP N
ESRS NNP N
] NNP N
, , N
UKU-Side JJ N
Effect NNP N
Rating NNP N
Scale NNP N
) ) N
were VBD N
performed VBN N
at IN N
12 CD N
, , N
16 CD N
, , N
20 CD N
and CC N
24 CD N
weeks NNS N
, , N
following VBG N
the DT N
12 CD N
week NN N
double-blind JJ N
phase NN N
. . N

Rose NNP N
geranium NN N
( ( N
Pelargonium NNP N
graveolens VBZ N
, , N
Geraniaceae NNP N
) ) N
has VBZ N
anti-cancer JJ N
and CC N
anti-inflammatory JJ N
properties NNS N
, , N
and CC N
promotes VBZ N
wound IN N
healing VBG N
. . N

The DT N
roots NNS N
of IN N
these DT N
teeth NNS N
were VBD N
fixed VBN N
in IN N
acrylic JJ N
resin NN N
cylinders NNS N
, , N
and CC N
brackets NNS N
were VBD N
bonded VBN N
to TO N
the DT N
teeth NN N
's POS N
crowns NNS N
using VBG N
the DT N
following JJ N
material NN N
combinations NNS N
: : N
RMGIC NNP N
only RB N
; : N
RMGIC NNP N
and CC N
corresponding VBG N
primer NN N
; : N
RMGIC NNP N
, , N
acid NN N
etching NN N
, , N
and CC N
Scotchbond NNP N
Multipurpose NNP N
; : N
RMGIC NNP N
and CC N
two-step JJ N
self-etching JJ N
primer NN N
; : N
and CC N
RMGIC NNP N
and CC N
one-step JJ N
primer NN N
. . N

Clinical JJ N
failure NN N
was VBD N
associated VBN N
with IN N
( ( N
i NN N
) ) N
placebo NN N
treatment NN N
( ( N
adjusted VBN N
OR NNP N
= $ N
1.28 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.01 CD N
to1.62 NN N
) ) N
, , N
( ( N
ii NN N
) ) N
excess JJ N
respiratory JJ N
rate NN N
of IN N
> $ N
10 CD N
breaths NNS N
per IN N
minute NN N
( ( N
adjusted VBN N
OR NNP N
= $ N
1.51 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.19 CD N
, , N
1.92 CD N
) ) N
, , N
( ( N
iii NN N
) ) N
vomiting VBG N
at IN N
enrolment NN N
( ( N
adjusted VBN N
OR NNP N
= $ N
1.49 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.13 CD N
, , N
1.96 CD N
) ) N
, , N
( ( N
iv NN N
) ) N
history NN N
of IN N
use NN N
of IN N
broncho-dilators NNS N
( ( N
adjusted VBN N
OR NNP N
= $ N
1.71 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.30 CD N
, , N
2.24 CD N
) ) N
and CC N
( ( N
v NN N
) ) N
non-adherence NN N
( ( N
adjusted VBN N
OR NNP N
= $ N
8.06 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
4.36 CD N
, , N
14.92 CD N
) ) N
. . N

RESULTS NNP N
After IN N
the DT N
intervention NN N
period NN N
, , N
the DT N
diabetes NNS N
specific JJ N
formula NN N
resulted VBD N
in IN N
a DT N
significantly RB N
lower JJR N
postprandial JJ N
rise NN N
in IN N
blood NN N
glucose JJ N
concentrations NNS N
at IN N
0.5 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
1 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
significantly RB N
lower JJR N
peak JJ N
height NN N
of IN N
plasma NN N
glucose NN N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
; : N
significantly RB N
lower JJR N
plasma NN N
insulin NN N
concentrations NNS N
at IN N
0.5 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
1 CD N
hour NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
2 CD N
hours NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
; : N
and CC N
a DT N
significantly RB N
lower JJR N
plasma NN N
insulin NN N
peak NN N
compared VBN N
to TO N
controls NNS N
; : N
both DT N
OGTT NNP N
and CC N
a DT N
standard JJ N
test NN N
meal NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Compared VBN N
with IN N
the DT N
remaining VBG N
693 CD N
patients NNS p
, , N
subjects NNS N
with IN N
left JJ N
ventricular JJ N
thrombosis NN N
were VBD N
older JJR N
( ( N
mean NN N
( ( N
SD NNP N
) ) N
age NN N
: : N
64.6 CD N
( ( N
13.0 CD N
) ) N
v NN N
59.8 CD N
( ( N
11.7 CD N
) ) N
years NNS N
, , N
p NN N
< NNP N
0.005 CD N
) ) N
, , N
and CC N
had VBD N
larger JJR N
infarcts NNS N
( ( N
extent NN N
of IN N
wall NN N
motion NN N
asynergy NN N
: : N
40.9 CD N
( ( N
11.5 CD N
) ) N
% NN N
v JJ N
24.9 CD N
( ( N
14 CD N
) ) N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
greater JJR N
depression NN N
of IN N
left JJ N
ventricular JJ N
ejection NN N
fraction NN N
at IN N
S1 NNP N
( ( N
43.3 CD N
( ( N
6.9 CD N
) ) N
% NN N
v JJ N
48.1 CD N
( ( N
6.8 CD N
) ) N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
greater JJR N
left VBD N
ventricular JJ N
volumes NNS N
at IN N
S1 NNP N
( ( N
end VB N
diastolic NN N
volume NN N
: : N
87 CD N
( ( N
22 CD N
) ) N
v NN N
78 CD N
( ( N
18 CD N
) ) N
ml/m NN N
( ( N
2 CD N
) ) N
, , N
p JJ N
< VBP N
0.001 CD N
; : N
end VB N
systolic JJ N
volume NN N
: : N
50 CD N
( ( N
17 CD N
) ) N
v NN N
41 CD N
( ( N
14 CD N
) ) N
ml/m NN N
( ( N
2 CD N
) ) N
, , N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

PURPOSE VB N
The DT N
aims NNS N
of IN N
this DT N
pilot NN N
study NN N
were VBD N
the DT N
following JJ N
: : N
1 CD N
) ) N
to TO N
examine VB N
patterns NNS N
of IN N
adherence NN N
to TO N
a DT N
brisk JJ N
walking VBG N
program NN N
in IN N
women NNS N
receiving VBG N
adjuvant JJ N
chemotherapy NN i
or CC N
radiation NN N
therapy NN i
for IN N
newly RB N
diagnosed VBN N
breast NN N
cancer NN N
using VBG N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
experimental JJ N
design NN N
; : N
2 CD N
) ) N
to TO N
examine VB N
the DT N
influence NN N
of IN N
disease NN N
symptoms NNS N
and CC N
treatment NN N
side NN N
effects NNS N
on IN N
exercise NN N
levels NNS N
; : N
and CC N
3 CD N
) ) N
to TO N
suggest VB N
methods NNS N
that WDT N
may MD N
improve VB N
future NN N
clinical JJ N
trials NNS N
of IN N
moderate-intensity NN N
exercise NN N
in IN N
similar JJ N
populations NNS N
. . N

On IN N
follow-up NN N
, , N
the DT N
sevelamer NN N
group NN N
had VBD N
higher JJR N
levels NNS N
of IN N
intact JJ N
parathyroid JJ N
hormone NN N
( ( N
498 CD N
+/- JJ N
352 CD N
vs. FW N
326 CD N
+/- JJ N
236 CD N
pg/ml NN N
, , N
p NN N
= NNP N
0.017 CD N
) ) N
, , N
bone JJ N
alkaline NN N
phosphatase NN N
( ( N
38 CD N
+/- JJ N
24 CD N
vs. FW N
28 CD N
+/- JJ N
15 CD N
U/l NNP N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
and CC N
deoxypyridinoline NN N
( ( N
135 CD N
+/- JJ N
107 CD N
vs. FW N
89 CD N
+/- JJ N
71 CD N
nmol/l NN N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
and CC N
lower JJR N
LDL NNP N
cholesterol NN N
( ( N
74 CD N
+/- JJ N
21 CD N
vs. FW N
91 CD N
+/- JJ N
28 CD N
mg/dl NN N
, , N
p NN N
= NNP N
0.015 CD N
) ) N
. . N

Symptoms NNS N
of IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
were VBD N
assessed VBN N
( ( N
Social NNP N
Responsiveness NNP N
Scale-Parent NNP N
( ( N
SRS-P NNP N
) ) N
; : N
coded VBN N
in-session NN N
behavior NN N
) ) N
in IN N
typically-developing NN N
, , N
anxiety-disordered JJ N
children NNS N
( ( N
N NNP N
= NNP N
50 CD N
) ) N
treated VBN N
with IN N
cognitive-behavioral JJ N
therapy NN i
( ( N
CBT NNP N
) ) N
. . N

Two CD N
distinct JJ N
disease-oriented JJ N
high-dose JJ N
regimens NNS N
without IN N
total JJ N
body NN N
irradiation NN N
consisted VBD N
of IN N
the DT N
MCVAC NNP N
regimen NNS N
using VBG N
ranimustine NN N
( ( N
MCNU NNP N
, , N
450 CD N
mg/m2 NN N
) ) N
, , N
cytosine JJ N
arabinoside NN N
( ( N
16 CD N
g/m2 NN N
) ) N
, , N
etoposide RB N
( ( N
1.6 CD N
g/m2 NN N
) ) N
, , N
and CC N
